Industry Connections
SPONSORED CONTENT
This information is being distributed by the American Diabetes Association as a sponsor benefit. Reference to commercial products, processes, or services by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the American Diabetes Association. The views and opinions of sponsors expressed herein do not necessarily state or reflect those of the American Diabetes Association, and shall not be used for advertising or product endorsement purposes.
Founded in 2017, the Ohio Cardiovascular and Diabetes Health Collaborative (Cardi-OH) is a statewide initiative of health care professionals who share knowledge to improve Medicaid patient outcomes and eliminate health disparities across the state of Ohio. Subject matter experts at Ohio’s seven medical schools identify, produce, and disseminate evidence-based best practices for primary care teams. Check out Cardi-OH’s new and improved website, Cardi-OH.org, featuring an updated, comprehensive resource library and a robust search tool. Discover a collection of convenient tools, including curated articles, inspiring podcasts, valuable summaries of timely news, engaging webinars, a new web app for on-the-go access, and much more.
Don’t miss out on meeting Tandem Mobi, the world’s smallest, durable automated insulin delivery system1 — and the latest innovation from Tandem Diabetes Care. Learn about data presented at their product theatre, “Meet Tandem Mobi: Tiny pump, big control. The future of AID”, and explore the benefits of the impressively small AID system that offers wearability like never before. Tandem Mobi is powered by Control-IQ technology, which predicts and helps prevent highs and lows. Visit booth 1621 for more information about Tandem Mobi, the tiny pump that’s big on control. (Reference 1. As of June, 2024. Data on file, Tandem Diabetes Care.)
Decentralizing Diabetes Care: Supporting Remission through Timely Screening and Diabetes Specific Formula. On the path to diabetes remission, people with diabetes may face many challenges. Join us for a symposium that details the evidence based and ongoing research to meet patients where they are to support diabetes remission. Speakers will discuss access to timely screening, holistic diabetes education and care, as well as share new study insights on digitally enabled interventions and diabetes specific formula.
As more and more healthcare providers and people with type 1 diabetes uncover the advantages of the Omnipod 5 Automated Insulin Delivery (AID) System, it has become the #1 prescribed AID in the U.S.* With Forlenza et al publishing “Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes,” there is now even more evidence demonstrating the results this tubeless AID can offer to you and your patients. (*USA 2023, Data on file **Forlenza G, et al. Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes. Diabetes Technol Ther. 2024.)